Lack of significant association of an insertion/deletion polymorphism in the angiotensin converting enzyme (ACE) gene with tropical calcific pancreatitis by Bhaskar, Seema et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Gastroenterology
Open Access Research article
Lack of significant association of an insertion/deletion 
polymorphism in the angiotensin converting enzyme (ACE) gene 
with tropical calcific pancreatitis
Seema Bhaskar1, DN Reddy2, Swapna Mahurkar1, GV Rao2, Lalji Singh1 and 
Giriraj R Chandak*1
Address: 1Genome Research Group, Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad 500 007, India and 2Asian Institute of 
Gastroenterology, Punjagutta, Hyderabad 500 082, India
Email: Seema Bhaskar - seema@ccmb.res.in; DN Reddy - aigindia@yahoo.co.in; Swapna Mahurkar - mahurkar@ccmb.res.in; 
GV Rao - aigindia@yahoo.co.in; Lalji Singh - lalji@ccmb.res.in; Giriraj R Chandak* - chandakgrc@ccmb.res.in
* Corresponding author    
Abstract
Background: The genetic basis of tropical calcific pancreatitis (TCP) is different and is explained
by mutations in the pancreatic secretory trypsin inhibitor (SPINK1) gene. However, mutated
SPINK1 does not account for the disease in all the patients, neither does it explain the phenotypic
heterogeneity between TCP and fibro-calculous pancreatic diabetes (FCPD). Recent studies
suggest a crucial role for pancreatic renin-angiotensin system during chronic hypoxia in acute
pancreatitis and for angiotensin converting enzyme (ACE) inhibitors in reducing pancreatic fibrosis
in experimental models. We investigated the association of ACE gene insertion/deletion (I/D)
polymorphism in TCP patients using a case-control approach. Since SPINK1  mutations are
proposed a modifier role, we also investigated its interaction with the ACE gene variant.
Methods: We analyzed the I/D polymorphism in the ACE gene (g.11417_11704del287) in 171
subjects comprising 91 TCP and 80 FCPD patients and compared the allelic and genotypic
frequency in them with 99 healthy ethnically matched control subjects.
Results: We found 46% and 21% of TCP patients, 56% and 19.6% of FCPD patients and 54.5% and
19.2% of the healthy controls carrying the I/D and D/D genotypes respectively (P>0.05). No
significant difference in the clinical picture was observed between patients with and without the del
allele at the ACE in/del polymorphism in both categories. No association was observed with the
presence or absence of N34S SPINK1 mutation in these patients.
Conclusion: We conclude that the ACE insertion/deletion variant does not show any significant
association with the pathogenesis, fibrosis and progression of tropical calcific pancreatitis and the
fibro-calculous pancreatic diabetes.
Background
Chronic Pancreatitis (CP) is a major health care problem
worldwide and is associated with varied etiologies. CP is
identified clinically by loss of endocrine and/or exocrine
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functions and pathologically by the presence of chronic
inflammation and fibrosis of the pancreas [1,2]. Tropical
calcific pancreatitis (TCP) is a form of chronic pancreatitis
of unknown etiology, more prevalent in the tropical
regions of developing countries such as India whereas
fibrocalculous pancreatic diabetes (FCPD) is a form of
diabetes secondary to TCP [3]. Both TCP and FCPD are
associated with extensive fibrosis involving both intra and
inter-lobular regions and not limited to one zone of the
pancreas, although the extent of fibrosis varies and is usu-
ally more in FCPD [4]. We and several others previously
demonstrated an absence of mutations in the cationic
trypsinogen gene (PRSS1) and a higher frequency of N34S
mutation in the pancreatic secretory trypsin inhibitor
(encoded by SPINK1  gene) in both FCPD and TCP
patients without diabetes mellitus suggesting a common
genetic basis for them [5,6]. However, other genetic and/
or environmental factors may explain the phenotypic var-
iability in FCPD and TCP patients without diabetes [5].
The renin-angiotensin system (RAS) plays a central role in
health and disease by maintaining the electrolyte and
fluid balance and in turn, the blood pressure [7]. Apart
from circulating RAS, several studies suggest the existence
of local RAS components in tissues such as brain, heart,
kidney, pancreas, adrenals and gonads [8,9]. Tissue spe-
cific RAS can act locally as paracrine and/or autocrine fac-
tors in meeting specific needs of individual tissues [10]
and any functional alterations may be associated with
pathophysiology of respective tissue/organ functions [11-
13]. An intrinsic renin-angiotensin system (RAS) is
present in the pancreas. Angiotensin converting enzyme
(ACE), a zinc metallopeptidase is a key enzyme of this sys-
tem [14]. ACE and RAS activity is known to be enhanced
during acute pancreatitis and chronic hypoxia in experi-
mental animals [15,16]. ACE cleaves angiotensin (AT)-I to
AT-II, which induces proliferation of hepatic stellate cells
(HSCs) and synthesis of extracellular matrix proteins by
increasing the expression of transforming growth factor-
beta [17,18]. Isolated pancreatic stellate cells are similar to
HSCs [19] and known to be involved in pathogenesis of
pancreatic fibrosis in both experimental animals and
humans [20]. Increased accumulation of extra-cellular
matrix is a histological characteristic of chronic pancreati-
tis that results in pancreatic fibrosis [21]. In addition, ACE
inhibitors have recently been demonstrated to attenuate
pancreatic inflammation and fibrosis in spontaneously
occurring chronic pancreatitis in male Wistar Bonn/
Kobori rats [22].
A polymorphism within intron 16
(g.11417_11704del287) of the ACE  gene is strongly
related to the circulating enzyme levels in a dose depend-
ent manner [23]. The DD genotype that is associated with
higher levels of circulating ACE than the II and ID geno-
types, is known to be significantly more frequent in
patients with myocardial infarction or patients with dia-
betic proteinuria than in controls [24,25]. Thus, ACE gene
polymorphisms may play a role in the pathogenesis of
chronic pancreatitis and several other pancreatic diseases
including acute pancreatitis, pancreatic cancer, diabetes
mellitus and cystic fibrosis. Although a recent study failed
to find any association of ACE  I/D polymorphism in
familial and sporadic chronic pancreatitis, we hypothe-
sized a role for this polymorphism in view of the extensive
fibrosis observed in the TCP patients [26]. In this study,
we investigated the ACE gene I/D polymorphism in TCP
patients (without diabetes mellitus), FCPD patients and
healthy controls to understand its association with the
disease. Since, SPINK1 mutations are proposed to play a
modifier role, we also investigated whether any associa-
tion exists with the I/D polymorphism in the ACE gene.
Methods
Patients and controls
A total of 171 unrelated patients (120 M+51 F) compris-
ing of 91 TCP and 80 FCPD patients were recruited in the
study based on the WHO criteria [27]. 99 unrelated ethni-
cally matched individuals with complaints of dyspepsia
were recruited as controls after a similar set of investiga-
tions excluded the disease in them. These individuals
filled the same questionnaire and underwent similar
investigations as the patients especially the imaging pro-
cedures which included computed tomography, endo-
scopic ultrasonography, magnetic resonance cholangio-
pancreatography and endoscopic retrograde cholangio-
pancreatography, wherever indicated [5]. All the patients
and healthy controls were explained the purpose of the
study and the complications of investigative procedures
and peripheral blood samples were collected after they
signed the written informed consent. The study was
approved by the institutional ethics committee of respec-
tive institutes following the Indian Council of Medical
Research guidelines for handling human samples.
Genetic analysis
Genomic DNA was isolated from peripheral blood leuco-
cytes following standard protocols [28]. The genotype at I/
D variant was determined by PCR amplification of
genomic DNA fragment in intron 16 of the ACE  gene
using forward and reverse primers, 5'-CCACTCCCATC-
CTTTCTCC-3' and 5'-GGCCATCACATTCGTCAGA-3'
respectively. The position of the amplified region in the
gene covering the polymorphism was 11417–11595 (as
per NT_010783). PCR was performed using cycling condi-
tions of initial denaturation at 94°C for 3 min, followed
by 35 cycles of denaturation at 94°C for 1 min, annealing
at 59°C for 1 min and extension at 72°C for 1 min 30 sec,
with a final 5 min extension at 72°C. PCR products of
approximate 179 bp (without insertion) and approximateBMC Gastroenterology 2006, 6:42 http://www.biomedcentral.com/1471-230X/6/42
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466 bp (with 287 bp insertion) were detected by electro-
phoresis on a 2% agarose-gel containing ethidium bro-
mide as shown in figure 1. Genotyping was repeated if any
ambiguity was noted in the observations. The primer
sequences and PCR conditions for analysis of the pro-
moter region and four exons of the SPINK1 gene were
selected from Witt et al. [29]. All the exons were
sequenced individually on both the strands using internal
sequencing primers and Big dye terminator cycle sequenc-
ing ready kit and an ABI 3730 Genetic Analyzer (Applied
Biosystems) [5]. 10% of randomly selected samples were
sequenced to confirm the genotypes.
Statistical analysis
Allele frequency was calculated by the allele counting
method, which was then utilized to determine the geno-
type frequency. The patients were divided into TCP and
FCPD based on the presence or absence of diabetes melli-
tus and further based on the status of N34S SPINK1 muta-
tion and ACE in/del polymorphism. Statistical
comparisons were carried out by using Pearson's Chi-
squared test, unpaired t-test and odds ratios (OR) along
with the 95% confidence interval (CI). Two-tailed P val-
ues less than 0.05 were considered statistically significant.
Post-hoc power analysis showed the study being ade-
quately powered (84.6%) to accept the null hypothesis
that the I/D polymorphism in ACE gene is not associated
with TCP (α = 0.05, β = -1.426) [30].
Results and discussion
Tropical calcific pancreatitis is a form of chronic pancrea-
titis associated with fibrosis and pancreatic calcification.
FCPD, a form of diabetes secondary to TCP, is thought to
occur due to pancreatic destruction as a result of fibrosis
and calcification [3]. We investigated the association of I/
D polymorphism in the ACE gene with TCP and the phe-
notype of diabetes in FCPD.
The median age at onset and age at presentation for FCPD
patients was 32.6 yrs (95% CI 29.6–35.6) and 40.9 yrs
(95% CI 37.8–44.0), which is significantly higher than
that of TCP patients without diabetes mellitus [(25.8 yrs,
95% CI 23.5–28.1, P = 0.004) and (33.9 yrs, 95% CI
31.6–36.2, P = 0.001) respectively] (table 1). However,
the duration of disease was similar in either category. As
suggested earlier, FCPD represents a late stage manifesta-
tion of TCP [5,31].
We did not observe any significant difference either in the
allele frequency or in the genotype distribution of the I/D
polymorphism at ACE locus between patients and con-
trols (D allele frequency; 0.46 and 0.47 respectively) and
between TCP and FCPD patients (D allele frequency; 0.44
and 0.48 respectively) (table 2). No deviation from
Hardy-Weinberg equilibrium was observed (P>0.05).
Since frequency of mutated SPINK1 is reported to be sim-
ilar in TCP and FCPD patients [5,6], we investigated
whether the I/D variant in ACE gene can explain the phe-
notypic variability between them. We did not observe any
association of the ACE I/D polymorphism with various
phenotypic features including the age of onset and age of
presentation, pancreatic calcification or surgeries (table
3). Table 4 summarizes the allele frequency and genotype
distribution of I/D polymorphism in patients and the
controls based on the presence or absence of N34S
SPINK1 mutation (irrespective of their zygosity, hetero-
zygous or homozygous genotypes). Of 91 TCP patients,
60 carried the wild type allele while 31 (34%) had at least
one copy of the mutant allele at N34S SPINK1 variant.
Genotypic distribution of the I/D variant was similar in
the patient groups with and without N34S mutation in
SPINK1 gene as well as in TCP and FCPD patient group
and the normal individuals. Among TCP patients carrying
mutated SPINK1, 15 (48%) patients were heterozygous
for I/D ACE variant and 5 (16%) carried the DD genotype
whereas of 41 patients without N34S SPINK1 mutation,
27 (45%) had I/D genotype and 14 (23%) carried DD
genotype at the ACE  locus. Similar observations were
made for the group of 80 FCPD patients with and without
N34S mutation in the SPINK1 gene. This suggests that
there is no interaction between the I/D variant in the ACE
gene and the N34S mutation in the SPINK1 gene in either
TCP or FCPD patients. It may be interesting to investigate
whether other variants in the ACE gene or any specific
haplotype may explain the role of ACE in TCP and FCPD.
Angiotensin converting enzyme catalyzes the conversion
of angiotensin I into the vasoactive and aldosterone-stim-
ulating peptide angiotensin II [14], which carries out its
biological functions by binding to two receptors, AT1R
and AT2R [32]. Several studies have suggested the pres-
ence of a pancreatic RAS, having physiological effects via
a paracrine/autocrine pattern in the exocrine and endo-
crine pancreas, probably in the regulation of pancreatic
microcirculation, ductal anion secretion and islet hormo-
nal secretion [9]. Both circulating and intrinsic pancreatic
ACE activity is markedly elevated during acute and
chronic inflammation of the pancreas [15,16]. Recent
studies have shown that ACE enzyme directs pancreatic
fibrogenesis in experimental animals [33] and inhibition
of the RAS system with an ACE inhibitor attenuates pan-
creatic inflammation and fibrosis in an animal model of
chronic pancreatitis [22]. Thus, angiotensinogen-II con-
verted endogenously from angiotensinogen-I by circulat-
ing ACE may be directly involved in the induction of
pancreatic inflammation and development of pancreatic
fibrosis in the spontaneously occurring chronic pancreati-
tis in male Wistar Bonn/Kobori (WBN/Kob) rats [22].
However, our study failed to observe any associationBMC Gastroenterology 2006, 6:42 http://www.biomedcentral.com/1471-230X/6/42
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between I/D variant and TCP or FCPD patients irrespec-
tive of N34S SPINK1 mutation status.
Our results are in agreement with the recent study on
familial and sporadic chronic pancreatitis patients, which
showed that the insertion/deletion polymorphism in the
ACE gene does not make a significant contribution to the
pathogenesis and progression of the disease [26].
Although, recent evidence suggests that TCP is a specific
genetic entity [5], there may be certain overlapping fea-
tures with idiopathic chronic pancreatitis (ICP). In fact,
the nomenclature of idiopathic chronic pancreatitis is
itself a matter of debate since genetic etiology appears to
play an important role in both ICP and TCP in India [34].
Thus, ACE I/D polymorphism may not contribute to the
pathogenesis of TCP despite the fact that the RAS system
specifically affects the pancreas, an indication that local
effects are more important than the systemic ones in pan-
creatic diseases. In the absence of intra-pancreatic ACE
levels in these patients, there may exist a possibility that in
contrast to other tissues such as heart and renal tissue, DD
genotype does not influence the ACE gene expression and
consequently its levels in the pancreas.
Conclusion
We conclude that the insertion/deletion polymorphism at
the ACE locus does not play any role in the causation and
progression of TCP. Further studies focusing on other
environmental and/or genetic factors such as mutations in
the  CFTR  gene may explain the phenotypic variability
between TCP and FCPD patients.
Abbreviations
ACE Angiotensin converting enzyme
AT Angiotensin
CP Chronic pancreatitis
CI Confidence interval
Agarose gel electrophoresis showing genotypes at in/del polymorphism in the ACE gene (g.11417_11704del287) Figure 1
Agarose gel electrophoresis showing genotypes at in/del polymorphism in the ACE gene (g.11417_11704del287). Lanes 1 & 13 
represent DNA marker XIV (New England Biolabs, USA) and marker V (Boerhinger Manheim, Germany), Lane 2:Control for 
genotype ID, Lane 3:Control for genotype II, Lane 4:Control for genotype DD. Lanes 5, 8, 10 show II genotype, lanes 7 and 12 
are ID genotypes and lanes 6, 9, 11 carry the DD genotype. bp, base-pair
500 bp
200 bp
434 bp
184 bp
1    2     3     4     5     6      7     8    9    10   11   12    13
Table 1: Characteristics of the study population
TCP FCPD Total
n 91 80 171
Sex (Male/Female) 61 M/30 F 59 M/21 F 120 M/51 F
Age at onset (yrs) 25.8 (23.5–28.1) 32.6 (29.6–35.6) 28.0 (26.0–30.0)
Age at presentation (yrs) 33.9 (31.6–36.2) 40.9 (37.8–44.0) 36.4 (34.4–38.4)
Duration of symptoms (yrs) 8.8 (7.5–10.1) 10.0 (8.4–11.6) 9.3 (8.3–10.3)
Age at onset of diabetes (yrs) NA 33.8 (31.0–36.6) NA
Duration of diabetes (yrs) NA 7.2 (5.8–8.6) NA
n, number of patients; yrs, years; TCP, tropical calcific pancreatitis; FCPD, fibro-calculous pancreatic diabetes
NA, not applicable; Figures are quoted as median, range 95% CIBMC Gastroenterology 2006, 6:42 http://www.biomedcentral.com/1471-230X/6/42
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Table 2: Allele frequency and genotype distribution of I/D polymorphism at ACE locus in TCP patients & control subjects
Patients Controls P  Value
TCP FCPD Total TCP vs. FCPD TCP vs. controls FCPD vs. controls
n 91 80 171 99 - - -
Allele frequency
I 0.56 0.52 0.54 0.53 0.57 0.67 0.89
D 0.44 0.48 0.46 0.47
Genotype frequency based on the presence or 
absence of the mutant allele
II 0.33 (30) 0.24 (19) 0.29 (49) 0.26 (26) 0.16 0.28 0.74
ID + DD 0.67 (61) 0.76 (61) 0.71 (122) 0.74 (73)
n, number of individuals; TCP, tropical calcific pancreatitis; FCPD, fibro-calculous pancreatic diabetes; ACE, angiotensin converting enzyme; I/D, 
insertion/deletion polymorphism at ACE locus figures in parentheses indicate number of individuals; P values are represented on comparison of 
TCP with FCPD, TCP with controls and FCPD with controls.
Table 3: Clinical features of TCP and FCPD patients grouped according to their genotype at in/del polymorphism at ACE gene
TCP FCPD Total
II ID/DD P value II ID/DD P value II ID/DD P value
n 30 61 - 19 61 - 49 122 -
Sex (Male/Female) 22/8 39/22 - 17/2 42/19 - 39/10 81/41 -
Age at onset (yrs) 25.7 ± 11.1 24.8 ± 11.8 0.72 34.4 ± 15.1 31.2 ± 12.9 0.37 29.0 ± 13.3 28.0 ± 12.7 0.64
Age at presentation (yrs) 36.2 ± 11.8 32.7 ± 10.9 0.16 40.3 ± 17.0 38.9 ± 13.9 0.72 37.8 ± 14.0 35.8 ± 12.9 0.37
Age at onset of diabetes (yrs) NA NA NA 34.2 ± 13.9 33.7 ± 11.44 0.88 34.2 ± 13.9 33.7 ± 11.4 0.81
Pancreatic surgery 11 (36.67%) 24 (40%) 0.76 2 (10.53%) 4 (6.56%) 0.57 13 (26.53%) 28 (23.14%) 0.64
Calcification 30 (100%) 61 (100%) 1 19 (100) 61 (100) 1 49 (100) 122 (100) 1
Pseudocyst 2 (6.67%) 4 (6.6%) 1 0 (0%) 1 (1.64) 1 2 (4.08%) 5 (4.13%) 1
n, number of individuals; TCP, tropical calcific pancreatitis; FCPD, fibro-calculous pancreatic diabetes; ACE, angiotensin converting enzyme
I/D, insertion/deletion polymorphism at ACE locus; NA, not applicable; figures in parentheses indicate percentage; figures are quoted as mean ± SD
P values are represented on comparison of II vs ID+DD genotypes in TCP, FCPD and total patients
Table 4: Allele frequency and genotype distribution of I/D polymorphism at ACE locus in TCP patients and controls based on their 
N34S SPINK1 status
Patients Controls
TCP P Value FCPD P Value Total P Value
N34S SPINK1 mutation status Mutant* Wild Mutant# Wild Mutant Wild Mutant$ Wild
N 31 60 21 59 52 119 3 96
Allele frequency
I 0.60 0.54 0.39 0.55 0.51 0.57 0.58 0.53 0.48 0.67 0.53
D 0.40 0.46 0.45 0.49 0.42 0.47 0.33 0.47
Genotype frequency based on the 
presence or absence of the mutant 
allele
II 0.36 (11) 0.32 (19) 0.55 0.29 (06) 0.22 (13) 0.26 0.33 (17) 0.27 (32) 0.35 0.33 (01) 0.26 (25)
ID + DD 0.64 (20) 0.68 (41) 0.71 (15) 0.78 (46) 0.67 (35) 0.73 (87) 0.67 (02) 0.74 (71)
n, number of individuals; TCP, tropical calcific pancreatitis; FCPD, fibro-calculous pancreatic diabetes; ACE, angiotensin converting enzyme; I/D, 
insertion/deletion polymorphism at ACE locus figures in parentheses indicate number of individuals; P value is represented on comparison of N34S 
SPINK1 positive vs. N34S negative TCP, FCPD and total patients.
*, includes 9 N34S SPINK1 homozygotes and 22 heterozygotes; # includes 4 N34S SPINK1 homozygotes and 17 heterozygotes, $, includes 3 N34S 
SPINK1 heterozygotesBMC Gastroenterology 2006, 6:42 http://www.biomedcentral.com/1471-230X/6/42
Page 6 of 7
(page number not for citation purposes)
FCPD Fibrocalculous pancreatic diabetes
HSCs Hepatic stellate cells
ICP Idiopathic chronic pancreatitis
OR Odds ratio
PRSS1 Protease, serine, 1 (trypsin 1)
RAS Renin-angiotensin system
TCP Tropical calcific pancreatitis
SPINK1 Serine protease inhibitor, Kazal type I
WHO World Health Organization
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